These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7591913)

  • 1. Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times.
    Stamey TA
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):967-8; discussion 972. PubMed ID: 7591913
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
    Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
    Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Moreira DM; Gerber L; Thomas JA; Bañez LL; McKeever MG; Freedland SJ
    Int J Urol; 2012 Aug; 19(8):741-7. PubMed ID: 22487442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
    Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
    Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].
    Graefen M
    Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003
    [No Abstract]   [Full Text] [Related]  

  • 13. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
    Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
    D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
    Stock RG; Ho A; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):389-94. PubMed ID: 16965991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number.
    Ploussard G; Azancot V; Nicolaiew N; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    BJU Int; 2010 Nov; 106(9):1293-7. PubMed ID: 20456338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.